<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03255447</url>
  </required_header>
  <id_info>
    <org_study_id>R04240</org_study_id>
    <nct_id>NCT03255447</nct_id>
  </id_info>
  <brief_title>Peptide GAM Immunoadsorption Therapy in Autoimmune Membranous Nephropathy</brief_title>
  <acronym>PRISM</acronym>
  <official_title>Phase II Trial Investigating the Safety and Feasibility of Peptide GAM Immunoadsorption in Anti-PLA2R Positive Autoimmune Membranous Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manchester University NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fresenius AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Manchester University NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autoimmune Membranous Nephropathy is now understood to be a condition caused by the immune&#xD;
      system although the exact mechanism is not completely known. This study aims to remove the&#xD;
      offending part of the immune system using immunoadsorption to not only treat the disease but&#xD;
      also use the opportunity to better understand the mechanism of disease. This will allow more&#xD;
      targeted treatment in the future with less complications and side effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Membranous nephropathy (MN) is among the most common causes of nephrotic syndrome in adults&#xD;
      worldwide. The majority of patients will remain stable with either complete remission or&#xD;
      partial remission but approximately 20% will progress slowly to end stage renal disease&#xD;
      necessitating the need for renal replacement therapy (RRT).&#xD;
&#xD;
      Current standard therapy for primary (or autoimmune) membranous nephropathy is a regime of&#xD;
      rotating high dose steroids and immunosuppression was first described in the mid-nineties and&#xD;
      has been the mainstay of treatment since but comes with a high side effect burden.&#xD;
&#xD;
      Idiopathic membranous nephropathy is now understood to be an autoimmune disease characterised&#xD;
      by the presence of IgG autoantibodies to M-Type Phospholipase A2 Receptor (anti-PLA2R).&#xD;
      Immunoadsorption is a method of removing specific circulating immunoglobulins and has been&#xD;
      shown to remove over 80% of circulating IgG with a single session immunoadsorption of 2.5&#xD;
      plasma volumes, with albumin and antithrombin III almost unaffected. With multiple sessions&#xD;
      this can rise to over 98%.&#xD;
&#xD;
      Immunoadsorption therapy has been in use for a number of years and this study will use&#xD;
      Peptide GAM Immunoadsorption therapy developed by Fresenius Healthcare. This uses two&#xD;
      systems, the Art Universal and ADAsorb. The Art Universal became commercially available in&#xD;
      2005 and the ADAsorb in 2002.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2016</start_date>
  <completion_date type="Actual">April 3, 2019</completion_date>
  <primary_completion_date type="Actual">April 3, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum anti-PLA2R titres</measure>
    <time_frame>14 days</time_frame>
    <description>Reduction in serum anti-PLA2R titres to normal range</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of treatment related adverse events as defined by CTCAE v4.0</measure>
    <time_frame>Day 14, 28, 56, 84, 168 and 365</time_frame>
    <description>To assess the safety and tolerability of Immunoadosorption therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the effect on disease activity (efficacy)</measure>
    <time_frame>Day 14, 28, 56, 84, 168 and 365</time_frame>
    <description>Assessment of reduction in proteinuria level and change in eGFR from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum anti-PLA2R titres</measure>
    <time_frame>Day 14, 28, 56, 84, 168 and 365</time_frame>
    <description>Kinetic modelling of serum anti-PLA2R levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the effect on Quality of life measures (EQ5D)</measure>
    <time_frame>Day 14, 28, 56, 84, 168 and 365</time_frame>
    <description>To determine the effect on Quality of life measures (EQ5D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>Day 14, 28, 56, 84, 168 and 365</time_frame>
    <description>Cost-effectiveness of treatment (Incremental cost-effectiveness ratio)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Autoimmune Membranous Nephropathy</condition>
  <arm_group>
    <arm_group_label>Immunoadsorption therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peptide GAM immunoadsorption therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Immunoadsorption</intervention_name>
    <description>Fresenius Globaffin</description>
    <arm_group_label>Immunoadsorption therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy confirmed Primary Membranous Nephropathy within the last 3 years&#xD;
&#xD;
          -  Active disease despite 6 months of supportive care including ACEi or ARB (Active&#xD;
             disease defined as uPCR &gt; 300mg/mmol or 24 hour urinary protein &gt;3.5g/1.73m2)&#xD;
&#xD;
          -  Disease severity that in the physicians view warrants treatment prior to completion of&#xD;
             6 months supportive care&#xD;
&#xD;
          -  Anti-PLA2R titre &gt; 170 u/ml&#xD;
&#xD;
          -  Haemophilus and Pneumococcal vaccinations up to date&#xD;
&#xD;
          -  Above the age of 18&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of causes of secondary membranous nephropathy&#xD;
&#xD;
          -  eGFR &lt; 20ml/min&#xD;
&#xD;
          -  Treatment with steroids or immunosuppression (including but not limited to&#xD;
             cyclophosphamide, MMF or azathioprine) and Biologics (including but limited to&#xD;
             Rituximab or belimumab) within 6 months of screening&#xD;
&#xD;
          -  Therapeutic Plasma Exchange within 28 days of screening&#xD;
&#xD;
          -  Previous renal transplantation&#xD;
&#xD;
          -  Co-morbidity, which in physicians' view, would preclude patient from treatment with&#xD;
             immunoadsorption.&#xD;
&#xD;
          -  Pregnant at time of screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandip Mitra</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Manchester University Hospital Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Manchester University Hospital Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Preston Hospital</name>
      <address>
        <city>Preston</city>
        <state>Lancashire</state>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salford Royal Infirmary</name>
      <address>
        <city>Salford</city>
        <state>Lancashire</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 11, 2017</study_first_submitted>
  <study_first_submitted_qc>August 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2017</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic Membranous Nephropathy</keyword>
  <keyword>Primary Membranous Nephropathy</keyword>
  <keyword>Immunoadsorption</keyword>
  <keyword>Apharesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

